The efficacy of milnacipran in panic disorder: an open trial
The efficacy of milnacipran in panic disorder: an open trial
复制标题
DOI：
10.1097/yic.0b013e32802c7bf5
复制
发表时间：
2007-05-01
影响因子：
2.6
通讯作者：
Manfro, Gisele G.
中科院分区：
文献类型：
--
作者：
Blaya, Carolina;Seganfredo, Ana Carolina;Manfro, Gisele G.
本研究的目的是评价米那西普兰在急性惊恐障碍患者治疗中的疗效。31名符合《精神障碍诊断与统计手册- iv》恐慌障碍伴或不伴广场恐惧症标准的患者被纳入研究。患者最初使用米那西普兰25mg，每日两次，然后使用50mg，每日两次，直到第10周。治疗结果和惊恐障碍严重程度由惊恐障碍严重程度量表、惊恐量表、临床总体印象量表和汉密尔顿焦虑量表确定，并在每次评估访谈中应用。在基线和研究结束时评估生活质量（whoqol - brief）。缺失的数据通过对所有至少服用一剂研究药物的参与者进行结转的最后一次观察来处理。意向治疗用于分析。药物治疗导致所有严重程度测量的临床和统计学上显著的平均降低。缓解（临床总体印象）
The aim of this study is to evaluate the efficacy of milnacipran in the acute treatment of patients with panic disorder. Thirty-one patients who met Diagnostic and statistical manual of mental disorders-IV criteria for panic disorder with or without agoraphobia were included in the study. Patients were initially treated with milnacipran 25 mg twice daily and then 50 mg twice daily until the 10th week. The treatment outcome and panic disorder severity were determined by the Panic Disorder Severity Scale, Panic Inventory, Clinical Global Impression and Hamilton Anxiety Scale, all of which were applied during every evaluation interview. Quality of life (WHOQOL-bref) was evaluated at baseline and at the end of the study. Missing data were handled by using the last observation carried forward for all participants who had taken at least one dose of study medication. Intention-to-treat was used in the analyses. Pharmacological treatment resulted in a clinically and statistically significant mean reduction in all severity measures. Remission (Clinical Global Impression